CoChat

Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis

Robbins, Kevin, Bissonnette, Robert, Maeda-Chubachi, Tomoko, Ye, Li, Peppers, Johnny, Gallagher, Kelly, Kraus, John E. · 2019 · Journal of the American Academy of Dermatology
Cited by 93

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background: There is a significant need for novel, safe, and efficacious topical treatments for psoriasis. Objective: We assessed the safety and efficacy of tapinarof in a new cream formulation at 2 concentrations and with 2 application frequencies in adults with psoriasis. Methods: Double‐blind, vehicle‐controlled, randomized, 6‐arm trial (1:1:1:1:1:1) in adults, with psoriasis with body surface involvement ≥1% and ≤15% and Physician Global Assessment (PGA) score ≥2 at baseline. Primary endpoint included PGA of 0 or 1 at week 12 and a 2‐grade improvement from baseline. Additional analyses included assessment of ≥75% improvement of Psoriasis Area and Severity Index and mean percent change in Psoriasis Area and Severity Index and body surface area involvement. Results: Treatment success defined by PGA 0 or 1 and a 2‐grade improvement at week 12 was statistically significantly higher (at a .05 significance level) in the tapinarof groups (65% [1% twice daily], 56% [1% once daily], 46% [0.5% twice daily], and 36% [0.5% once daily]) than in the vehicle groups (11% [twice daily] and 5% [once daily]) and was maintained for 4 weeks posttreatment. Treatment‐emergent adverse events were more frequent in patients treated with tapinarof (85/152, 56%) than vehicle (19/75, 25%) and mild‐to‐moderate in intensity. Severe treatment‐emergent adverse events were reported in all tapinarof groups except the 0.5% once daily group. Limitations: Large confirmation trials are needed. Conclusions: Tapinarof cream is efficacious and well tolerated in adult patients with psoriasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaad.2018.10.037

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 93

Metadata

Authors
Robbins, K., Bissonnette, R., Maeda-Chubachi, T., Ye, L., Peppers, J., Gallagher, K., & Kraus, J. E.
Venue
Journal of the American Academy of Dermatology
Publisher
Elsevier BV
Published
2019-03
Volume
80
Issue
3
Pages
714-721
ISSN
0190-9622 (ISSN-L)
OpenAlex
W2898213950
Cited by
93
References
4
FWCI
3.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. https://app.cochat.ai/papers/10.1016/j.jaad.2018.10.037
The paper
Robbins, K., Bissonnette, R., Maeda-Chubachi, T., Ye, L., Peppers, J., Gallagher, K., & Kraus, J. E. (2019). Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2018.10.037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.